A pilot study on adults with type 2 diabetes using intermittent scanning continuous glucose monitoring (isCGM) found an 8 mmol/mol reduction in A1c that was not significant. However, the use of isCGM led to a significant 18% improvement in time in range (TIR). Participants using isCGM showed better outcomes in glucose levels compared to those using a “blinded” CGM. No serious adverse events were reported. The study suggests that isCGM could potentially benefit non-insulin-treated adults with type 2 diabetes by delaying insulin initiation and improving long-term outcomes. The study was conducted by Emmanuel Ssemmondo and colleagues and was published in Diabetes, Obesity, and Metabolism.
Source link
Sensor Technology Aids Those With Non-Insulin-Treated T2D
